EHA 2019 poster: PTC299 is a novel dihydroorotate dehydrogenase (DHODH) inhibitor for use in treatment of acute myeloid leukemia (AML)
This poster provides the results of ex vivo experiments using a novel inhibitor of DHODH, to investigate its potential as a treatment for AML. It was presented at the 2019 EHA meeting in Amsterdam Results presented include the range of leukemia cell lines found to be sensitive to treatment with the DHODH inhibitor Results showing activity against cancer cells in patient-derived xenografts mouse models are displayed, along with efficacy of the novel agent in primary AML blood samples from human patients The mechanism of action by which the agent selectively targets AML cells by pyrimidine deprivation is presented
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AML-2100046 | October 2021
Close Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our
Privacy Statement and our Terms and Conditions do not apply.
MED-ALL-CORP-2200029 | December 2022
Close COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available,